The Q2 23 results were driven by robust momentum for the firm’s GLP-1 diabetes drugs and obesity portfolio. While the management again upgraded the 2023 guidance, the markets seemed disappointed with the continued restrictions on the Wegovy supply. Overall, despite the stellar growth prospects and laudable operating performance, we remain cautious in terms of our recommendation, as Novo trades at expensive valuations on the back of the obesity market frenzy.
